Clovis Oncology (NASDAQ:CLVS) insider Patrick J. Mahaffy purchased 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $5.59 per share, for a total transaction of $279,500.00. Following the completion of the purchase, the insider now owns 919,187 shares of the company’s stock, valued at $5,138,255.33. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
CLVS opened at $6.06 on Thursday. The business’s fifty day moving average is $10.07 and its two-hundred day moving average is $18.39. The company has a current ratio of 3.57, a quick ratio of 3.32 and a debt-to-equity ratio of 8.04. Clovis Oncology has a one year low of $4.98 and a one year high of $37.27.
Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($2.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.70) by ($0.57). The firm had revenue of $32.98 million for the quarter, compared to analysts’ expectations of $34.92 million. Clovis Oncology had a negative return on equity of 372.68% and a negative net margin of 332.18%. The firm’s revenue for the quarter was up 38.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.94) earnings per share. Analysts forecast that Clovis Oncology will post -7.44 earnings per share for the current fiscal year.
A number of research firms recently weighed in on CLVS. G.Research restated a “buy” rating on shares of Clovis Oncology in a research note on Friday, August 2nd. Guggenheim downgraded Clovis Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Royal Bank of Canada set a $26.00 price target on Clovis Oncology and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, HC Wainwright restated a “buy” rating on shares of Clovis Oncology in a research note on Wednesday, July 3rd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $25.09.
About Clovis Oncology
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.